Lorcaserin Inhibit Glucose-Stimulated Insulin Secretion and Calcium Influx in Murine Pancreatic Islets
Lorcaserin is a serotonergic agonist specific to the 5-hydroxytryptamine 2c receptor (5-HT2CR) that is FDA approved for the long-term management of obesity with or without at least one weight-related comorbidity. Lorcaserin can restrain patients’ appetite and improve insulin sensitivity and hyperins...
Saved in:
Main Authors: | Muhan Jing, Shanshan Wang, Ding Li, Zeyu Wang, Ziwen Li, Yichen Lu, Tong Sun, Chen Qiu, Fang Chen, Haijuan Yu, Wei Zhang |
---|---|
Format: | article |
Language: | EN |
Published: |
Frontiers Media S.A.
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/adfc739abd40432680c62a204c56bcf9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
by: Hurt RT, et al.
Published: (2018) -
Gαi/o-coupled Htr2c in the paraventricular nucleus of the hypothalamus antagonizes the anorectic effect of serotonin agents
by: Eun-Seon Yoo, et al.
Published: (2021) -
Structural Basis of Type 2 Secretion System Engagement between the Inner and Outer Bacterial Membranes
by: Iain D. Hay, et al.
Published: (2017) -
Diabetic Retinopathy and Insulin Insufficiency: Beta Cell Replacement as a Strategy to Prevent Blindness
by: Eli Ipp
Published: (2021) -
Lorcaserin for weight management
by: Taylor JR, et al.
Published: (2013)